Leptin Signaling in Lean and Obese Humans

Obesity Clinical Trial

— Leptin signali  

Official title:

Leptin Signaling in Humans

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01297426
• Other study ID #: ENDA-013-10F
• Status: Withdrawn
• Phase: N/A
• First received: February 14, 2011
• Last updated: December 23, 2015
• Start date: April 2011
• Est. completion date: June 2015

Study information

• Verified date: December 2015
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

Obesity does not respond to high circulating levels of the hormone leptin. This study is aiming at finding out why this happens and open new avenues for treatment of obesity.

Description:

Ex vivo and in vitro identification and study of leptin signaling pathways in commercially available cell lines serum/ plasma samples and discarded tissues from humans.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• men and women

• ages 18 to 65

• BMI ranges between 20 and 45 kg/m2

Exclusion Criteria:

• subjects requiring special diets

• history of illness other than obesity of diabetes

• taking medications known to influence glucose metabolism

• subjects with history of anaphylactic reaction or hypersensitivity to e. coli derived proteins or anesthetic agents

• women who are breastfeeding, pregnant or wanting to become pregnant

• subjects with bleeding dyscrasia or poor wound healing

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Obesity

Locations

Country	Name	City	State
United States	VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Westerns / activation of signaling pathways (uo to two hours after treatment)		04/01/2016	No